Key result
Sex hormones and gender-specific risk factors shape HF onset and progression despite uniform treatments.
Why the study?
Women remain underrepresented in clinical trials, leaving the synergistic or opposing effects of sex hormones on heart failure mechanisms poorly clarified despite substantial sex differences in disease onset, progression, and clinical course.
This review highlights the importance of understanding sex-specific pathophysiological mechanisms and the role of sex hormones in heart failure to advance precision medicine.
Supports sex-specific HF research; leaves open whether uniform treatments should be revised.
Patients with heart failure are conventionally stratified into phenotypic groups based on their ejection fraction. The aim of this stratification is to improve disease management with a more targeted therapeutic approach. A further subdivision based on patient gender is justified. It is recognized that women are underrepresented in randomized controlled clinical trials, resulting in limited clinical and molecular differentiation between males and females. However, many observational studies show that the onset, development, and clinical course of the disease may substantially differ between the two sexes. According to the emerging concept of precision medicine, investigators should further explore the mechanisms responsible for the onset of heart failure due to sex differences. Indeed, the synergistic or opposing effects of sex hormones on the cardiovascular system and underlying heart failure mechanisms have not yet been clarified. Sex hormones, risk factors impact, and cardiovascular adaptations may be relevant for a better understanding of the intrinsic pathophysiological mechanisms in the two sexes. Despite the differences, treatment for HF is similar across the whole population, regardless of sex and gender. In our review, we describe the main differences in terms of cardiovascular dysfunction, risk factors, and cellular signaling modifications related to the hormonal pattern.
No takes yet. Share an insight, caveat, or question.
Delcuratolo et al. (2023) conducted a review in Heart failure. Sex hormones and gender-specific risk factors significantly influence the onset, development, and clinical course of heart failure, despite current treatments remaining similar across both sexes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: